ciprofloxacin has been researched along with Polyomavirus Infections in 16 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Polyomavirus Infections: Infections with POLYOMAVIRUS, which are often cultured from the urine of kidney transplant patients. Excretion of BK VIRUS is associated with ureteral strictures and CYSTITIS, and that of JC VIRUS with progressive multifocal leukoencephalopathy (LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of the current study was to evaluate the safety and efficacy of ciprofloxacin for the prevention of BK viremia in kidney transplant recipients." | 9.30 | Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial. ( Gaber, AO; Graviss, EA; Knight, RJ; Kuten, SA; Moore, LW; Musick, WL; Nguyen, DT; Patel, SJ, 2019) |
| " Ciprofloxacin prophylaxis appears safe and effective in reducing the incidence of severe BKHC after allogeneic HSCT." | 5.37 | Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. ( Costa, LJ; Glode, A; Hogan, KR; Kramer, C; Miller, AN; Schaub, C; Stuart, RK, 2011) |
| " The purpose of the current study was to evaluate the safety and efficacy of ciprofloxacin for the prevention of BK viremia in kidney transplant recipients." | 5.30 | Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial. ( Gaber, AO; Graviss, EA; Knight, RJ; Kuten, SA; Moore, LW; Musick, WL; Nguyen, DT; Patel, SJ, 2019) |
| "This analysis demonstrates for the first time that, used in a stepwise fashion, ciprofloxacin and leflunomide are effective and safe treatments for BK viremia in PRTR." | 3.80 | A novel treatment regimen for BK viremia. ( Cheam, H; Ettenger, RB; Malekzadeh, MH; Tsai, EW; Zaman, RA, 2014) |
| "Ciprofloxacin treatment reduced the viral load and improved the clinical findings." | 1.38 | BK virus nephropathy developing after renal transplantation and its treatment with ciprofloxacin: a case report. ( Bakirdoven, S; Cekmen, MB; Sayan, M; Yilmaz, A, 2012) |
| " Ciprofloxacin prophylaxis appears safe and effective in reducing the incidence of severe BKHC after allogeneic HSCT." | 1.37 | Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. ( Costa, LJ; Glode, A; Hogan, KR; Kramer, C; Miller, AN; Schaub, C; Stuart, RK, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, SJ | 1 |
| Knight, RJ | 1 |
| Kuten, SA | 1 |
| Graviss, EA | 1 |
| Nguyen, DT | 1 |
| Moore, LW | 1 |
| Musick, WL | 1 |
| Gaber, AO | 1 |
| Umbro, I | 1 |
| Anzivino, E | 1 |
| Tinti, F | 1 |
| Zavatto, A | 1 |
| Bellizzi, A | 1 |
| Rodio, DM | 1 |
| Mancini, C | 1 |
| Pietropaolo, V | 1 |
| Mitterhofer, AP | 1 |
| Zeidan, S | 1 |
| Esposito, L | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Zaman, RA | 1 |
| Ettenger, RB | 1 |
| Cheam, H | 1 |
| Malekzadeh, MH | 1 |
| Tsai, EW | 1 |
| Flores, V | 1 |
| Rodríguez-Sánchez, B | 1 |
| Marín-Jiménez, I | 1 |
| Bouza, E | 1 |
| Menchén, L | 1 |
| Muñoz, P | 1 |
| Halim, MA | 2 |
| Al-Otaibi, T | 2 |
| Gheith, O | 1 |
| Zkaria, Z | 1 |
| Mosaad, A | 1 |
| Said, T | 2 |
| Nair, P | 2 |
| Nampoory, N | 1 |
| Gagneux-Brunon, A | 1 |
| Pillet, S | 1 |
| Laurent, B | 1 |
| Mariat, C | 1 |
| Michalet, M | 1 |
| Lucht, F | 1 |
| Botelho-Nevers, E | 1 |
| Jun, JB | 1 |
| Choi, Y | 1 |
| Kim, H | 1 |
| Lee, SH | 1 |
| Jeong, J | 1 |
| Jung, J | 1 |
| Koukoulaki, M | 1 |
| Apostolou, T | 1 |
| Hadjiconstantinou, V | 1 |
| Drakopoulos, S | 1 |
| El-Kholy, O | 1 |
| Gheith, OA | 1 |
| Al-Waheeb, S | 1 |
| Szucs, G | 1 |
| Pacsa, A | 1 |
| Balaha, MA | 1 |
| Hasaneen, H | 1 |
| Nampoory, MR | 1 |
| Miller, AN | 1 |
| Glode, A | 1 |
| Hogan, KR | 1 |
| Schaub, C | 1 |
| Kramer, C | 1 |
| Stuart, RK | 1 |
| Costa, LJ | 1 |
| Wojciechowski, D | 1 |
| Chanda, R | 1 |
| Chandran, S | 1 |
| Lee, B | 1 |
| Webber, A | 1 |
| Macaraig, M | 1 |
| Tomlanovich, S | 1 |
| Vincenti, F | 1 |
| Cekmen, MB | 1 |
| Bakirdoven, S | 1 |
| Sayan, M | 1 |
| Yilmaz, A | 1 |
| Leung, AY | 1 |
| Chan, MT | 1 |
| Yuen, KY | 1 |
| Cheng, VC | 1 |
| Chan, KH | 1 |
| Wong, CL | 1 |
| Liang, R | 1 |
| Lie, AK | 1 |
| Kwong, YL | 1 |
| Randhawa, PS | 1 |
| Thamboo, TP | 1 |
| Jeffery, KJ | 1 |
| Friend, PJ | 1 |
| Turner, GD | 1 |
| Roberts, IS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients[NCT01789203] | Phase 4 | 200 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| BK Viremia and BK Virus Nephropathy Post Kidney Transplant Comparison of New Practices With Traditional Approach: A Combined Retrospective Chart Review and Prospective Observational Study[NCT02758288] | 0 participants (Actual) | Observational | 2015-09-30 | Withdrawn | |||
| Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study[NCT01034176] | Phase 4 | 43 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Proportion of patients developing BK viremia at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 31 |
| Placebo | 8 |
Clostridium difficile infection at 6 months (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 0 |
Patient death at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 1 |
First BK plasma viral loads (NCT01789203)
Timeframe: 12 months
| Intervention | copies/mL (Median) |
|---|---|
| Ciprofloxacin | 2514 |
| Placebo | 1423 |
kidney failure within first 1 year of transplant (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 25 |
| Placebo | 5 |
Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 3 |
| Placebo | 2 |
Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 17 |
| Placebo | 14 |
Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 15 |
| Placebo | 7 |
Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month) (NCT01789203)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 35 |
| Placebo | 18 |
Median time to initial BK viremia episode, days (NCT01789203)
Timeframe: 12 months
| Intervention | days (Median) |
|---|---|
| Ciprofloxacin | 90 |
| Placebo | 76.5 |
Number of patients with >50% reduction in BK viral load at 6 months (NCT01034176)
Timeframe: Baseline and 6 months
| Intervention | participants (Number) |
|---|---|
| Levofloxacin | 15 |
| Placebo | 13 |
Percent change in BK virus copies/mL from Baseline to 3 months (NCT01034176)
Timeframe: Baseline and 3 months
| Intervention | Percent change of BK virus copies (Median) |
|---|---|
| Levofloxacin | 70.3 |
| Placebo | 69.1 |
2 trials available for ciprofloxacin and Polyomavirus Infections
| Article | Year |
|---|---|
Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial.
Topics: Adult; BK Virus; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Humans; Immunosuppres | 2019 |
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Ciprofloxacin; Female; H | 2005 |
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Ciprofloxacin; Female; H | 2005 |
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Ciprofloxacin; Female; H | 2005 |
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Ciprofloxacin; Female; H | 2005 |
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Ciprofloxacin; Female; H | 2005 |
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Ciprofloxacin; Female; H | 2005 |
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Ciprofloxacin; Female; H | 2005 |
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Ciprofloxacin; Female; H | 2005 |
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; BK Virus; Ciprofloxacin; Female; H | 2005 |
14 other studies available for ciprofloxacin and Polyomavirus Infections
| Article | Year |
|---|---|
Possible antiviral effect of ciprofloxacin treatment on polyomavirus BK replication and analysis of non-coding control region sequences.
Topics: Adult; Anti-Bacterial Agents; BK Virus; Ciprofloxacin; DNA, Intergenic; DNA, Viral; Humans; Kidney T | 2013 |
The Achilles tendon of preventing BK virus nephropathy.
Topics: Achilles Tendon; Anti-Bacterial Agents; BK Virus; Ciprofloxacin; Humans; Kidney Diseases; Kidney Tra | 2013 |
A novel treatment regimen for BK viremia.
Topics: Adolescent; BK Virus; Child; Ciprofloxacin; Female; Fluoroquinolones; Glomerular Filtration Rate; Hu | 2014 |
Prospective study of BK virus infection in patients with inflammatory bowel disease.
Topics: Adolescent; Adult; Age Factors; Aged; BK Virus; Case-Control Studies; Ciprofloxacin; Female; Humans; | 2014 |
Active management versus minimization of immunosuppressives of BK virus-associated nephropathy after a kidney transplant.
Topics: Adult; Antiviral Agents; Biopsy; BK Virus; Ciprofloxacin; Drug Substitution; Drug Therapy, Combinati | 2014 |
A case of BK virus nephropathy in a stem cell transplant recipient: a rare or under-recognized cause for Acute Kidney injury.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; BK Virus; Ciprofloxacin; Cord Blood Stem Cell Transplant | 2015 |
BK polyomavirus encephalitis in a patient with thrombotic microangiopathy after an allogeneic hematopoietic stem cell transplant.
Topics: Anemia, Hemolytic; Anti-Bacterial Agents; Antiviral Agents; BK Virus; Cidofovir; Ciprofloxacin; Cyst | 2016 |
Impact of prophylactic administration of ciprofloxacin on BK polyoma virus replication.
Topics: Adult; Aged; Antiviral Agents; BK Virus; Ciprofloxacin; DNA, Viral; Drug Administration Schedule; Fe | 2008 |
Active management of post-renal transplantation BK virus nephropathy: preliminary report.
Topics: Adult; Anti-Infective Agents; Biopsy; BK Virus; Ciprofloxacin; Creatinine; Female; Histocompatibilit | 2009 |
Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients.
Topics: Adult; Aged; Anti-Infective Agents; BK Virus; Ciprofloxacin; Cystitis; Female; Hematologic Neoplasms | 2011 |
Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year.
Topics: Adult; Aged; Anti-Infective Agents; BK Virus; Chi-Square Distribution; Ciprofloxacin; Drug Administr | 2012 |
BK virus nephropathy developing after renal transplantation and its treatment with ciprofloxacin: a case report.
Topics: Antiviral Agents; BK Virus; Ciprofloxacin; Humans; Kidney Diseases; Kidney Transplantation; Male; Po | 2012 |
Anti-BK virus activity of ciprofloxacin and related antibiotics.
Topics: Anti-Infective Agents; BK Virus; Ciprofloxacin; Humans; Polyomavirus Infections; Tumor Virus Infecti | 2005 |
Anti-BK virus activity of ciprofloxacin and related antibiotics.
Topics: Anti-Infective Agents; BK Virus; Ciprofloxacin; Humans; Polyomavirus Infections; Tumor Virus Infecti | 2005 |
Anti-BK virus activity of ciprofloxacin and related antibiotics.
Topics: Anti-Infective Agents; BK Virus; Ciprofloxacin; Humans; Polyomavirus Infections; Tumor Virus Infecti | 2005 |
Anti-BK virus activity of ciprofloxacin and related antibiotics.
Topics: Anti-Infective Agents; BK Virus; Ciprofloxacin; Humans; Polyomavirus Infections; Tumor Virus Infecti | 2005 |
Urine cytology screening for polyoma virus infection following renal transplantation: the Oxford experience.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Immunosuppression Therapy; Kidney Diseases; Kidney Tra | 2007 |